Zinger Key Points
- Bausch Health Companies expects 2024 revenues of $9.4 billion-$9.65 billion versus consensus of $9.397 billion.
- The company expects adjusted EBITDA of $3.21 billion-$3.36 billion versus the prior guidance of $3.20 billion-$3.35 billion.
On Thursday, Bausch Health Companies BHC reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28.
The company reported revenues of $2.403 billion, up 11% year-over-year, beating the consensus of $2.339 billion.
Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenue increased by 8% organically compared with the second quarter of 2023.
Guidance: Bausch Health Companies expects 2024 revenues of $9.4 billion-$9.65 billion versus prior guidance of $9.3 billion-$9.55 billion and consensus of $9.397 billion.
The company expects adjusted EBITDA of $3.21 billion-$3.36 billion versus the prior guidance of $3.20 billion-$3.35 billion.
Piper Sandler analyst downgraded Bausch to Underweight from Neutral and lowered its price target to $3, a significant decline from $9.
The analyst highlights that with around $9.4 billion in debt maturing in 2027/2028 and Xifaxan set to lose exclusivity by January 2028, Bausch’s solvency remains a critical concern despite their efforts to shift focus.
The conversation inevitably returns to solvency issues even with developments like the next-generation rifaximin formulation (RED-C).
In the second quarter of 2024, Xifaxan sales increased by 10% year over year.
Bausch Health is promoting RED-C, which is in late-stage development, to prevent a first episode of hepatic encephalopathy (HE).
However, since Xifaxan is already approved to prevent HE recurrence, it is anticipated that Xifaxan generics may be used off-label for the initial prevention of HE if RED-C gets approved.
Therefore, it is uncertain whether RED-C will significantly impact Xifaxan’s market share once it loses exclusivity.
Last week, Bausch Health Companies stock witnessed a sharp decline triggered by a report suggesting the company is negotiating a potential prepackaged Chapter 11 bankruptcy with co-op creditor.
The company later issued a statement, firmly denying any discussions related to bankruptcy or insolvency proceedings.
Price Action: BHC stock is down 6.80% at $5.69 at the last check on Friday.
Read Next:
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
